Iron, Copper, Zinc, Magnesium, and Calcium in Postmortem Brain Tissue from Schizophrenic Patients

Johannes Kornhuber, Klaus W. Lange, Paul Kruzik, Wolf-Dieter Rausch, Eberhard Gabriel, Kurt Jellinger, and Peter Riederer

The regional distribution of iron, copper, zinc, magnesium, and calcium in postmortem brain of schizophrenic patients was compared with that of matched controls. In none of the brain regions investigated (caudate nucleus, hippocampus, amygdala, cortex, corpus mamillare, gyrus cinguli, and hypothalamus) were significant differences observed between these two groups. In the total group, region-specific differences were found for iron, copper, zinc, and calcium, but not for magnesium. Gender differences were observed only for zinc. There was no correlation between a neuroleptic-free period before death and the content of any of the metals investigated, except for a positive correlation between copper in the hippocampus and a neuroleptic-free period. The results of the present study suggest that there are no profound differences in the content of iron, copper, zinc, magnesium, and calcium in postmortem brains between controls and schizophrenic patients.

Key Words: Iron, copper, zinc, magnesium, calcium, schizophrenia, human brain, glutamate hypothesis, tardive dyskinesia, neuroleptic medication

Introduction

Transition metals such as iron, copper, and zinc are known to play a crucial role in various physiological functions in mammalian brains, for example, in prosthetic groups of metalloenzymes and in the control of gene expression (O'Halloran 1993). Transition metals have been linked primarily to neurological disorders such as Wilson's disease, Hallervorden-Spatz syndrome, Parkinson's disease and Alzheimer's disease (e.g., Riederer et al 1989; Constantinidis 1991; Good et al 1992). Considering the critical role of transition metals in enzyme and receptor function, however, excess or deficiency of these elements might also be related to the pathophysiology of schizophrenia.

Zinc is unevenly distributed within the brain with particularly high concentrations in the hippocampal mossy fiber system, where it acts as a neuromodulator (Xie and Smart 1991). Interactions with inhibitory (Smart and Constantinidis 1991) and excitatory amino acid neurotransmission (Yet et al 1990) are well known. Although low to moderate concentrations of zinc attenuate N-methyl-D-aspartate (NMDA)-mediated and enhance quisqualate-mediated neurotoxicity (Koh and Choi 1988), high concentrations of zinc are neurotoxic (Yokoyama et al 1986). Zinc deficiency has been hypothesized to be an important factor in the pathogenesis of neurodegenerative diseases.
of schizophrenia (Kimura and Kumura 1965; Pfeiffer and Iliev 1972; Andrews 1990).

Enhanced concentrations of zinc could be linked to the pathophysiology of schizophrenia, too. The glutamate hypothesis of schizophrenia proposes that a deficiency in glutamatergic neurotransmission and a resulting disturbance in balance between glutamatergic and dopaminergic systems within the basal ganglia may play a key role in the pathophysiology of schizophrenia (Kim et al 1980; Komhuber et al 1989a). Zinc inhibits transmission at the NMDA receptor (Yeh et al 1990). Enhanced activity of zinc at the NMDA receptor might thus be involved in the pathophysiology of schizophrenia. Results of direct measurements of zinc in human postmortem brain tissue are inconsistent. Kimura and Kumura (1965) found a 50% decrease in the zinc concentration in the hippocampus of schizophrenic patients and McLardy (1973) found a 30% reduction in zinc content in the brains of patients with early onset schizophrenia. Greiner et al (1975) found no differences in zinc content in several brain regions, however, the hippocampus was not investigated by these authors. No consistent differences in the content of zinc were found in cerebrospinal fluid (Potkin et al 1982) or plasma (Gillin et al 1982) of schizophrenic patients.

There are several findings linking schizophrenia to disturbed iron metabolism. Iron exerts a profound influence on dopaminergic neurotransmission and behavior in laboratory animals (Yehuda and Youdim 1988). Low serum iron levels were reported in patients suffering from neuroleptic-induced side effects, that is, akathisia (Brown et al 1987) and neuroleptic malignant syndrome (Rosebush and Mazurek 1991). Some investigators had the impression of increased iron staining in postmortem brain tissue (Josephy 1930; Stevens 1982). Recently, iron was quantified in postmortem brains from schizophrenic patients using optical density measurements of coronal sections stained with the Pearl's technique (Casanova et al 1992). In that study staining intensity of iron was significantly increased in the caudate nucleus, which was attributed to neuroleptic therapy.

The main support for a copper hypothesis of schizophrenia comes from repeated findings of elevated copper and coeruleoplasmin concentrations in the serum of schizophrenic patients (Bowman and Lewis 1982). Several copper-dependent enzymes are involved in catecholamine metabolism. More recent investigations, however, found unchanged copper levels in plasma and urine (Gillin et al 1982), cerebrospinal fluid (Shore et al 1983), and brain (Greiner et al 1975) of schizophrenic patients.

Besides the above-mentioned transition metals, changes in calcium and magnesium levels have also been linked to the pathophysiology of schizophrenia (Alexander and Jackson 1981). Direct measurements of these metals in postmortem human brain tissue have revealed no significant abnormalities in schizophrenia (Greiner et al 1975), however. The aim of the present study is to assess the content of iron, copper, zinc, magnesium, and calcium in several brain regions of schizophrenic patients and controls.

Materials and Methods

Postmortem handling of the autopsy material was similar in all cases. Brains were obtained at autopsy from 12 subjects (10 women, 2 men) with no history of neurological or psychiatric disorders. Control subjects had a mean age of 75.3 ± 7.1 years (± SD, range 41–91 years). This group was compared to 11 schizophrenic patients (6 women, 5 men) diagnosed according to both Feighner et al (1972) and to the International Classification of Diseases (ICD-9). These patients had a mean age of 69.6 ± 8.2 years (range 57–80 years). The diagnostic subgroups according to the ICD-9 were schizophrenia simplex (ICD 295.0, n = 1), hebephrenic subtype (ICD 295.1, n = 1), paranoid subtype (ICD 295.3, n = 1), chronic schizophrenia (ICD 295.6, n = 7), and schizoaffective psychosis (ICD 295.7, n = 1). Because there may be racial difference in the metabolism of certain metals (Potkin et al 1982), only brain specimens from Caucasian patients were investigated. Histopathological examination was performed on all brains to exclude other abnormalities such as tumor, infarction, anoxia, brain atrophy, and Alzheimer’s disease. Postmortem delay time (i.e., time between death and freezing) was less than 24 hr in all cases. A detailed examination of case notes was made to establish whether the patients had received neuroleptic medication during the period leading up to death. Three patients had been drug-free for at least 1 year and 7 patients were drug-free for at least 3 months. Putamen samples from all the schizophrenic patients and three of the controls had previously been analyzed for [H]spiperone binding (Komhuber et al 1989b). Brain tissue was taken from the caudate nucleus, hippocampus, amygdala, cortex, corpus mamillare, gyrus cinguli, and hypothalamus from both hemispheres. It was not possible to collect samples of all seven regions from every brain (Table 1). The tissue was quickly frozen and stored at −70°C until analysis.

Iron, copper, zinc, magnesium, and calcium were determined by an atomic absorption procedure (Stevens 1970). Thawed tissue was freeze-dried at −60°C and 10−2 T for 24 hr. Thereafter, the dry tissue was weighed and dissolved in acid-washed vials with 1 ml of 65% nitric acid p.a. at 110°C. The evaporated dry residue was taken up into 5 ml of the diluent. Atomic absorption spectroscopy was performed using a Zeiss PMQ II spectrophotometer.

Results are expressed as micrograms per gram dry weight. Mean values are given ± SD. Nonparametric statistics (Mann-Whitney U-test, Fisher’s exact probability test, Spearman’s rank correlation, Kruskal-Wallis one-way ANOVA) were used throughout using the two-tailed approach. P-values higher than 0.05 were regarded as not
Table 1. Case Data and Results of Metal Analysis in Postmortem Human Brains of Schizophrenic Patients (S) and Controls (C)

<table>
<thead>
<tr>
<th>Gender</th>
<th>n</th>
<th>M/F</th>
<th>Age (yrs)</th>
<th>Iron (μg/g dry weight)</th>
<th>Copper (μg/g dry weight)</th>
<th>Zinc (μg/g dry weight)</th>
<th>Magnesium (μg/g dry weight)</th>
<th>Calcium (μg/g dry weight)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caudate nucleus</td>
<td>9</td>
<td>3/6</td>
<td>72.7 ± 14.7</td>
<td>450.9 ± 167.6</td>
<td>26.0 ± 6.6</td>
<td>67.2 ± 17.5</td>
<td>589.2 ± 126.4</td>
<td>265.3 ± 234.2</td>
</tr>
<tr>
<td>S</td>
<td>8</td>
<td>4/5</td>
<td>76.6 ± 9.3</td>
<td>221.9 ± 42.7</td>
<td>18.0 ± 3.4</td>
<td>86.3 ± 13.0</td>
<td>556.2 ± 172.1</td>
<td>368.9 ± 210.3</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>9</td>
<td>1/8</td>
<td>70.8 ± 7.6</td>
<td>207.5 ± 27.3</td>
<td>19.9 ± 4.0</td>
<td>83.8 ± 10.2</td>
<td>582.4 ± 147.2</td>
<td>267.0 ± 110.8</td>
</tr>
<tr>
<td>Amygdala</td>
<td>9</td>
<td>1/8</td>
<td>75.6 ± 15.1</td>
<td>221.7 ± 57.8</td>
<td>20.6 ± 11.2</td>
<td>73.2 ± 15.5</td>
<td>1370.5 ± 2458</td>
<td>259.5 ± 164.6</td>
</tr>
<tr>
<td>S</td>
<td>11</td>
<td>5/6</td>
<td>69.6 ± 8.2</td>
<td>211.6 ± 45.7</td>
<td>18.8 ± 4.2</td>
<td>72.9 ± 14.6</td>
<td>541.0 ± 174.5</td>
<td>219.9 ± 89.7</td>
</tr>
<tr>
<td>Cortex</td>
<td>C</td>
<td>3</td>
<td>1/2</td>
<td>75.0 ± 10.0</td>
<td>219.7 ± 13.0</td>
<td>23.0 ± 5.3</td>
<td>76.2 ± 9.4</td>
<td>734.7 ± 51.5</td>
</tr>
<tr>
<td>S</td>
<td>7</td>
<td>3/4</td>
<td>68.9 ± 8.6</td>
<td>195.9 ± 24.2</td>
<td>22.5 ± 2.7</td>
<td>73.5 ± 9.4</td>
<td>612.4 ± 133.9</td>
<td>492.4 ± 285.1</td>
</tr>
<tr>
<td>Corpus mamillare</td>
<td>C</td>
<td>5</td>
<td>1/4</td>
<td>77.0 ± 10.6</td>
<td>303.2 ± 122.1</td>
<td>19.0 ± 2.1</td>
<td>44.4 ± 9.5</td>
<td>483.0 ± 176.3</td>
</tr>
<tr>
<td>S</td>
<td>6</td>
<td>2/3</td>
<td>67.6 ± 10.2</td>
<td>251.6 ± 54.4</td>
<td>24.1 ± 4.9</td>
<td>59.9 ± 14.3</td>
<td>625.6 ± 106.6</td>
<td>450.6 ± 171.2</td>
</tr>
<tr>
<td>Gyrus cinguli</td>
<td>C</td>
<td>5</td>
<td>1/4</td>
<td>78.8 ± 8.8</td>
<td>166.4 ± 48.5</td>
<td>20.6 ± 2.2</td>
<td>58.9 ± 22.0</td>
<td>604.2 ± 80.6</td>
</tr>
<tr>
<td>S</td>
<td>6</td>
<td>3/4</td>
<td>68.5 ± 9.4</td>
<td>235.8 ± 111.3</td>
<td>21.4 ± 2.9</td>
<td>75.5 ± 15.7</td>
<td>664.7 ± 43.8</td>
<td>516.3 ± 232.2</td>
</tr>
<tr>
<td>Hypothalamus</td>
<td>C</td>
<td>4</td>
<td>0/4</td>
<td>78.5 ± 9.3</td>
<td>160.4 ± 58.7</td>
<td>23.2 ± 7.0</td>
<td>44.5 ± 10.4</td>
<td>625.8 ± 285.4</td>
</tr>
<tr>
<td>S</td>
<td>5</td>
<td>1/4</td>
<td>71.0 ± 8.0</td>
<td>290.2 ± 170.5</td>
<td>23.2 ± 6.7</td>
<td>60.3 ± 16.2</td>
<td>450.0 ± 64.8</td>
<td>1173.0 ± 1766.5</td>
</tr>
</tbody>
</table>

Tissue samples from the different regions were not available from all brains. Therefore, the case data are listed for each region separately. Mean values are given ± SD.

Table 2. Effect of Brain Region on Metal Concentration (by Kruskal-Wallis One-Way ANOVA)

<table>
<thead>
<tr>
<th>Gender</th>
<th>n</th>
<th>M/F</th>
<th>Age (yrs)</th>
<th>Iron (μg/g dry weight)</th>
<th>Copper (μg/g dry weight)</th>
<th>Zinc (μg/g dry weight)</th>
<th>Magnesium (μg/g dry weight)</th>
<th>Calcium (μg/g dry weight)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>c</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Schizophrenics</td>
<td>c</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Total Group</td>
<td>c</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
</tbody>
</table>

NS = not significant. *p < 0.05. **p < 0.01. ***p < 0.001.

to women, either in the total group or in schizophrenics (data not shown). In the total group there was a gender difference in zinc content only in the hippocampus (76.2 ± 6.2 in men versus 88.6 ± 10.6 in women, μg/g dry weight, p < 0.01). In schizophrenic patients, there was a gender difference in the caudate nucleus (47.6 ± 12.3 in men versus 65.9 ± 13.1 in women, μg/g dry weight, p < 0.05) and in the hippocampus (77.1 ± 6.8 in men versus 88.3 ± 8.8 in women, μg/g dry weight, p < 0.05). There was no correlation between the neuroleptic-free period before death and the content of any of the metals investigated, except for a positive correlation between copper and the neuroleptic-free period in the hippocampus (r = 0.83, p < 0.02). One schizophrenic female aged 77 years had suffered from tardive dyskinesia before death. In this patient, the contents of all metals investigated were within the mean ± 2 SD range of schizophrenic patients without tardive dyskinesia.

Discussion
The metal concentrations and the regional distributions found in this study were generally in accordance with previous investigations on human brain material (Harrison et al 1968; Völkl and Ule 1972; Ule et al 1974; Riederer et al 1989). In none of the brain regions investigated significant differences were observed between schizophrenics and controls. Because a number of the patients will have received long-term antipsychotic drug treatment, it is conceivable that this may have had an effect on the content of the metals investigated. Theoretically, a preexisting difference in the metal content could have been masked by neuroleptic drugs. Except for the copper content in the hippocampus, however, the neuroleptic-free time before death had no impact on the metal concentrations. The functional signifi-
cance of the positive correlation between copper level and neuroleptic-free time before death should not be over-inter-
preted because of the explorative nature of the study (no 
α-corrections were applied).

Taken together, the results of the present study show that

there are no profound differences in the content of iron,
copper, zinc, magnesium, and calcium in brain tissue of
controls and schizophrenic patients. The results are there-
fore in full agreement with the earlier study by Greiner et al
(1975).

References

Alexander PE, Jackson AH (1981): Calcium and magnesium: rela-
tionship to schizophrenia and neuroleptic-induced extrapy-
ramidal symptoms. In Alexander PE (ed) Electrolytes and Neu-

Andrews RCR (1990): Unification of the findings in schizophre-
ia by reference to the effects of gestational zinc deficiency.

Bowman MB, Lewis MS (1982): The copper hypothesis of schizo-

Brown KW, Glen SE, White T (1987): Low serum iron status and

Staining intensity of brain iron in patients with schizophrenia:
A postmortem study. J Neuropsychiatry Clin Neurosci 4:36–
41.

Constantinis J (1991): The hypothesis of zinc deficiency in the
pathogenesis of neurofibrillary tangles. Med Hypotheses
35:319–323.

Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G,
Munoz R (1972): Diagnostic criteria for use in psychiatric
research. Arch Gen Psychiatry 26:57–63.

Gillin JC, Carpenter WT, Hambridge KM, Wyatt RJ, Henkin RI
(1982): Zinc and copper in patients with schizophrenia. L'ENCE-
éphale 8:435–444.

accumulation of aluminum and iron in the neurofibrillary tangles
of Alzheimer’s disease: a laser microprobe (LAMMA) study.

Greiner AC, Chan SC, Nicolson GA (1975): Human brain contents
of calcium, copper, magnesium and zinc in some neurological

Harrison WW, Netsky MG, Brown MD (1968): Trace elements in
human brain: copper, zinc, iron, and magnesium. Clin Chim

Joseph H (1930): Dementia praecox (Schizophrenie). In Burnke

Low cerebrospinal fluid glutamate in schizophrenic patients
and a new hypothesis on schizophrenia. Neurosci Lett 64:279–
382.

Kimura K, Kumura J (1965): Preliminary report on metabolism of
trace elements in neuropsychiatric diseases. 1. Zinc in schizoph-


\( ^{3} \)HJMK-801 binding sites in postmortem brain regions of

Kornhuber J, Riederer P, Reynolds GP, Beckmann H, Jellinger K,
Gabriel E (1989b): \( ^{3} \)H-Spiperone binding sites in post-mortem

brains from schizophrenic patients: Relationship to neuroleptic
drug treatment, abnormal movements, and positive symptoms.

McLardy T (1973): Hippocampal zinc in chronic alcoholism and
schizophrenia. IRCS Med Sci 2:1010.

O’Halloran TV (1993): Transition metals in control of gene ex-

Pfeiffer CC, Iliev V (1972): Zinc deficiency and copper excess in

zinc concentrations in ex-heroin addicts and patients with
schizophrenia: some preliminary observations. Biol Psychiatry
17:1315–1322.

ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J
Neurochem 52:515–520.

Rosebusch PI, Mazurek MF (1991): Serum iron and neuroleptic

concentrations in chronic schizophrenia. Am J Psychiatry

Smart TG, Constanti A (1990): Differential effect of zinc on the
vertebrate GABA\( _{A} \) receptor complex. Br J Pharmacol 99:643–
654.

Stevens BJ (1970): Clinical Applications of Atomic Absorption
Spectroscopy. Australia: Varian Techtron.

Stevens JR (1982): Neuropathology of schizophrenia? Arch Gen

Ule G, Völkl A, Berlet H (1974): Spurenelemente im menschli-
en Gehirn. II. Kupfer-, Zink-, Calcium- und Magnesiumkonz-
zentration in 13 verschiedenen Hirnregionen während der 4.
bis 8. Lebensdekade im Vergleich zum Hirnreisen. Z Neurol

Altersabhängigkeit der Eisenkonzentration in 13 verschiede-

Xie X, Smart TG (1991): A physiological role for endogenous zinc
in rat hippocampal synaptic neurotransmission. Nature
349:521–524.

Yeh G-C, Bonhaus DW, McNamara JO (1990): Evidence that zinc
inhibits N-methyl-D-aspartate receptor-gated channel activa-
tion by noncompetitive antagonism of glycine binding. Mol
Pharmacol 38:14–19.

Yehuda S, Youdim MBH (1988): Brain iron deficiency: biochem-
istry and behaviour. In Youdim MBH (ed) Brain Iron.
Neurochemical and Behavioural Aspects. London: Taylor & Francis,
pp 89–114.

Yokoyama M, Koh J, Choi DW (1986): Brief exposure to zinc is